On June 1st, 2023, XtalPi announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform to do de novo design and deliver drug candidates for an undisclosed target.
XtalPi’s AI + robotics platform is supercharging the shift of pharmaceutical R&D from labor-intensive trial-and-error research to a computation and automation-intensive model, empowering scientists to achieve more with less time and cost. With serving over 200 pharmaceutical clients and research institutions from around the world, XtalPi is now bringing its proprietary autonomous lab to Cambridge, MA, as its drug discovery business continues to grow.
Sep 25, 2024
